The invention relates to methods, systems and kits for determining therapeutic effectiveness or toxicity of cancer-treating compounds that incorporate into or bind to DNA. In particular, the invention is directed to methods, systems and kits for predicting a patient's treatment outcome after administration of a microdose of therapeutic composition to the patient. The methods provides physicians with a diagnostic tool to segregate cancer patients into differential populations that have a higher or lower chance of responding to a particular therapeutic treatment.

A blood analyzer according to one or more embodiments may include: a specimen preparation part that prepares a measurement specimen by mixing a reagent into a blood preparation; a measurement part that measures the measurement specimen; a measurement mode selection unit that receives an input of a type of blood preparation as a measurement target selected from a plurality of types of blood preparations; and a controller. The controller may cause the specimen preparation part to prepare the measurement specimen depending on the selected type of blood preparation.

A blood analyzer according to one or more embodiments may include: a specimen preparation part that prepares a measurement specimen by mixing a reagent into a blood preparation; a measurement part that measures the measurement specimen; a measurement mode selection unit that receives an input of a type of blood preparation as a measurement target selected from a plurality of types of blood preparations; and a controller. The controller may cause the specimen preparation part to prepare the measurement specimen depending on the selected type of blood preparation.

Artificial blood for a bloodstain pattern analysis includes water, an amino acid solution, bovine serum albumin, hemoglobin from bovine blood, potassium ferricyanide, sodium hyaluronate, sodium chloride, and tar color.

Artificial blood for a bloodstain pattern analysis includes water, an amino acid solution, bovine serum albumin, hemoglobin from bovine blood, potassium ferricyanide, sodium hyaluronate, sodium chloride, and tar color.

This invention describes a method for preparation of stable hematology reference materials by producing synthetic hydrogel blood cell surrogates, which mimic human blood components in size, morphology, performance and functionality when analyzed using an automated hematology analyzer employing multiple detection technologies. Different hydrogel particles can be combined and mixed to prepare multi-parameter and multi-level hematology reference materials, which could be used for calibration, linearity verification, proficiency evaluation, and routine performance monitoring of modern automated hematology analyzers. These hydrogel particles can also be combined with processed and stabilized human blood components to prepare the reference materials of this invention.

This invention describes a method for preparation of stable hematology reference materials by producing synthetic hydrogel blood cell surrogates, which mimic human blood components in size, morphology, performance and functionality when analyzed using an automated hematology analyzer employing multiple detection technologies. Different hydrogel particles can be combined and mixed to prepare multi-parameter and multi-level hematology reference materials, which could be used for calibration, linearity verification, proficiency evaluation, and routine performance monitoring of modern automated hematology analyzers. These hydrogel particles can also be combined with processed and stabilized human blood components to prepare the reference materials of this invention.

A method for assigning an antibody standard and determining a minimum detection limit of an antibody detection reagent specifically includes the following steps: S1, determination of a neutralized antigen equivalent of an antibody standard or a sample: an antigen with a known purity and concentration is subjected to a gradient dilution using a matrix, an equal amount of an antibody standard or antibody-containing sample is added to each of the gradient diluents with different concentrations respectively, and after a reaction, each mixture is subjected to an antibody detection using a first antibody detection reagent, to determine the neutralized antigen equivalent of the antibody standard or sample; S2, determination of an antibody titer of the sample; and S3, acquisition of the minimum detection limit of an antibody detection reagent.

Methods and kits for determining the efficiency of plasma separation from whole blood are provided, using real-time PCR amplification of two amplicons, namely, a short amplicon of e.g. 70-150 bps and a long amplicon of e.g. 350-600 bps. The separation efficiency is determined based on the difference in amplification patterns of the two amplicons.

A method for assigning an antibody standard and determining a minimum detection limit of an antibody detection reagent specifically includes the following steps: S1, determination of a neutralized antigen equivalent of an antibody standard or a sample: an antigen with a known purity and concentration is subjected to a gradient dilution using a matrix, an equal amount of an antibody standard or antibody-containing sample is added to each of the gradient diluents with different concentrations respectively, and after a reaction, each mixture is subjected to an antibody detection using a first antibody detection reagent, to determine the neutralized antigen equivalent of the antibody standard or sample; S2, determination of an antibody titer of the sample; and S3, acquisition of the minimum detection limit of an antibody detection reagent.